Koura sanctions multi million-pound investment into Zephex® 152a facility
Leading medical propellant manufacturer and supplier, Koura, have announced a multi million-pound investment into a new laboratory facility based at their new medical division HQ at Thornton Science Park, Chester, UK.
The facility will be the first in the world to offer dedicated pharmaceutical grade laboratories specialising in the new low carbon footprint medical propellant Zephex® 152a and will create several highly skilled scientific and technical roles based onsite.
With an operational date set for late 2020, the new facility will allow pharmaceutical companies to develop and test new formulations for the treatment respiratory diseases including asthma based on Zephex® 152a.
This investment is part of a wider business strategy to offer additional services and facilities in support of the launch of Zephex® 152a to the global medical propellants market.
Simon Gardner, Pharma General Manager – Koura, say’s ‘Zephex® 152a is a leap forward in medical propellant development, both from an efficacy and environmental standpoint. With this investment we are expanding our services in support of our customers and their pharmaceutical development programmes and taking another important step to move closer to Zephex® 152a launching.’
Paul Watkinson, Pharma Project Manager – Koura, say’s this is both a challenging and exciting project, that enables us to move further downstream into a new business area. We have assembled a very capable project team comprising both Koura and external specialist resource. The project will enable Koura to establish small scale GMP MDI manufacturing and testing capability.